

ABCB1, *CYP2B6*, and *CYP3A4* genetic polymorphisms do not affect methadone maintenance treatment in HCV-positive patients

Davorka Sutlović^{1,2}, Željko Ključević³, and Sendi Kuret^{1,4}

¹ University of Split Department for Health Studies, Split, Croatia

² University of Split School of Medicine, Department of Toxicology and Pharmacogenetics, Split, Croatia

³ Public Health Institute of the Split-Dalmatia County, Department of Mental Health, Prevention and Outpatient Addiction Treatment, Split, Croatia

⁴ University Hospital Centre Split, Department of Pathology and Forensic Medicine, Split, Croatia

[Received in December 2019; Similarity Check in December 2019; Accepted in November 2020]

The aim of this study was to determine the influence of *ABCB1*, *CYP2B6*, and *CYP3A4* genetic polymorphisms on methadone metabolism in patients with hepatitis C virus (HCV) undergoing methadone maintenance treatment (MMT). The study included 35 participants undergoing MMT, who were divided in three groups: HCV-positive (N=12), HCV-negative (N=16), and HCV clinical remission (CR) (N=7). The concentrations of methadone and its main metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) were determined with gas chromatography-mass spectrometry. The patients were genotyped for *ABCB1* rs1045642, *CYP2B6* rs3745274, *CYP3A4* rs2242480, and *CYP3A4* rs2740574 polymorphisms. Differences between single nucleotide polymorphism (SNP) genotypes and methadone-to-EDDP ratio were analysed with one-way ANOVA, which showed no significant difference between the genes ($p=0.3772$ for *ABCB1* rs1045642, $p=0.6909$ for *CYP2B6* rs3745274, and $p=0.6533$ for *CYP3A4* rs2242480). None of the four analysed SNP genotypes correlated with methadone-to-EDDP concentration ratio. A major influence on it in hepatitis C-positive patients turned out to be the stage of liver damage.

KEY WORDS: EDDP; genotyping; hepatitis C; liver damage; SNP

Methadone is a synthetic opioid used for detoxification and maintenance treatment of patients who are dependent on opiates, mainly heroin. In the liver it is metabolised to 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) through *N*-demethylation mediated by several cytochrome P450 (CYP) enzymes, including *CYP3A4* and *CYP2B6* (1). The *CYP3A4* enzyme metabolises both (*R*)- and (*S*)-methadone enantiomers, but the (*S*)-enantiomer is mostly metabolised by *CYP2B6* (2, 3).

Methadone kinetics is also slightly affected by *ABCB1* genetic polymorphisms (4). In a study of their effects on methadone maintenance treatment (MMT) in 60 opioid-dependent patients, Coller et al. (5) reported that *ABCB1* genetic variability influenced daily methadone requirements.

In addition, *CYP* gene variants may contribute to the risk of fatal methadone toxicity posed by high concentrations of unmetabolised methadone in plasma (6). The risk may be even greater in patients with liver damage caused by hepatitis C virus (HCV) infection, which is common in opioid dependency. Our earlier studies (7, 8) have shown

that chronic overdose and liver insufficiency (damage) increase the amount of unmetabolised methadone and its toxicity, but we did not consider the influence of the *ABCB1*, *CYP2B6*, and *CYP3A4* genes on methadone metabolism as one of the numerous factors that influence inter-individual variability in that respect. The aim of this study was therefore to address this gap and see if the *ABCB1*, *CYP2B6*, and *CYP3A4* genetic polymorphisms affect methadone metabolism in patients on MMT.

MATERIALS AND METHODS

The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the University Hospital Split, Croatia (No. 530-01/12-01/164). All patients signed informed consent to participation in the study.

Participants

Our study participants were 35 adult men aged ≥ 21 years, who were in the MMT programme conducted by the Institute for Public Health of the Split-Dalmatia County, Croatia. To arrive to this number we first assessed for

Corresponding author: Davorka Sutlović, University of Split Department for Health Studies, Ruđera Boškovića 35, 21000 Split, Croatia
E-mail: dsutlovic@ozs.unist.hr



eligibility 74 adult male heroin addicts in the programme according to the following inclusion criteria: male, Caucasian, at least 9 months on MMT with regular attendance, no HIV or HBV co-infection or infection, negative urine tests for the presence of heroin or other pharmacological substances that could interfere with methadone metabolism, and no liver cirrhosis or history of significant alcohol abuse. HCV-positive patients were receiving interferon therapy that does not interfere with methadone metabolism (9). Thirty-nine candidates who did not meet these criteria were excluded.

The remaining 35 participants were divided in groups according to their HCV status: HCV-negative (HCV-) (N=12), HCV positive (HCV+) (N=16), and those in clinical remission (HCV CR) (N=7). Their liver damage was assessed according to the fibrosis-4 (FIB-4) index as described elsewhere (10). They were receiving different recommended doses of oral methadone based on their clinical presentation, and these doses were not modified for at least six months before the study (Table 1).

Methadone and EDDP determination

For this study, methadone and EDDP concentrations were tested only in urine during three regular check-ups 15 days apart. We took two urine samples per check-up; one immediately before and the other 90 min after oral methadone administration, which totalled six samples per participant. The samples were stored at 4 °C and analysed within 1–4 days as described in detail in our previous reports (8, 11). Methadone and EDDP concentrations were used to calculate their ratio (Table 1).

DNA analysis

Blood samples for DNA analysis were collected at regular check-ups and stored in EDTA tubes. DNA was isolated with a commercial genomic DNA isolation kit (High Pure PCR Template Preparation Kit, Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. Extracted DNA was quantified using a Qubit 4 fluorimeter (Thermo Fischer Scientific, Waltham, MA, USA).

SNP genotyping

Using the TaqMan® SNP genotyping assay (Thermo Fischer Scientific) and an Applied Biosystems 7500 real-time polymerase chain reaction (RT-PCR) system (Applied Biosystems, Foster City, CA, USA) we genotyped for the

following single-nucleotide polymorphisms (SNPs): *ABCB1* rs1045642 (DME C_7586657_20), *CYP2B6* SNP rs3745274 (DME C_7817765_60), *CYP3A4* rs2242480 (DME C_26201900_30), and *CYP3A4* rs2740574 (DME C_1837671_50). RT-PCR and allelic discrimination analyses were performed according to the manufacturer’s instructions in a 25-mL reaction volume. The temperature program for RT-PCR was 60 °C for 1 min and 95 °C for 10 min, followed by 50 cycles of 92 °C for 15 s and 60 °C for 90 s. SNP genotypes were determined using instrument software with the manual allele call option.

Statistical analysis

Statistics and differences between the samples and groups were tested by using GraphPad Prism version 8.0.0 for Mac (GraphPad Software, San Diego, CA, USA). Hardy-Weinberg equilibrium, chi-square, and the *p* value were calculated with an on-line calculator (12).

RESULTS AND DISCUSSION

Methadone is converted to its inactive metabolites EDDP and EMDP by hepatic CYP450 enzymes. Its pharmacokinetics is individual, not only because of differences in sex, age, body weight, and use of other drugs, but also because of different allelic frequencies of genetic polymorphisms (2). Some earlier studies have already shown that allelic variations in the *ABCB1* rs1045642, *CYP2B6* rs3745274, and *CYP3A4* rs2242480 and rs2740574 SNPs may affect the distribution of methadone in patients undergoing MMT (6, 13, 14).

Table 2 shows the genotypes of the four investigated SNP loci in DNA obtained from blood samples. Genotype frequencies were consistent with the Hardy-Weinberg equilibrium and did not significantly differ for any of the studied SNPs (the *p* value ranged from 0.55 to 0.93). Minor allele frequencies (MAF) (Table 2) were consistent with those presented in a meta study by Dennis et al. (15), in which they ranged between 24.5 and 50 % for *ABCB1* rs1045642 and between 24 and 39 % for *CYP2B6* rs3745274.

In contrast to *ABCB1* and *CYP2B6* SNPs, no mutated alleles were found in either of the analysed *CYP3A4* SNPs (Figure 1).


We observed a small difference in wild and mutant genotypes between the *ABCB1* and *CYP2B6* genes. Patients with the *ABCB1* AA and *CYP2B6* TT genotype had a slower

Table 1 Average FIB-4 index, methadone-to-EDDP urine concentration ratio, and methadone dose received by study groups (N=35)

Parameters	HCV-negative (n=12)	HCV-positive (n=16)	HCV clinical remission (n=7)
FIB-4 index	0.81	2.61	2.08
Methadone-to-EDDP urine concentration ratio	0.87	2.04	0.79
Methadone dose (mg)	83.2	85.0	62.5

Table 2 Genotype and allele frequencies (%) by loci for the *ABCB1*, *CYP2B6* and *CYP3A4* genes in all participants (N=35)

Gene	SNP	Genotype	n (%)	Minor allele	MAF (%)	Hardy-Weinberg equilibrium	
						p allele frequency	χ^2 p-value
<i>ABCB1</i>	rs1045642	GG	12 (34.3)	A	42.9	0.57	0.15 0.69
		AG	16 (45.7)				
		AA	7 (20)				
<i>CYP2B6</i>	rs3745274	GG	15 (42.9)	T	32.9	0.67	0.36 0.55
		GT	17 (48.5)				
		TT	3 (8.6)				
<i>CYP3A4</i>	rs2242480	CC	30 (85.7)	T	7.1	0.93	0.21 0.65
		CT	5 (14.3)				
		TT	0 (0)				
<i>CYP3A4</i>	rs2740574	TT	34 (97.1)	C	1.4	0.99	0.007 0.93
		CT	1 (2.9)				
		CC	0 (0)				

**Figure 1** Methadone-to-EDDP ratio in all patients with different *ABCB1*, *CYP2B6*, *CYP3A4* 480 and *CYP3A4* 574 variants. H – heterozygotes; M – mutant; wt – wild type




Figure 2 Methadone-to-EDDP ratio in patients with different *ABCB1* and *CYP2B6* variants by HCV status. H – heterozygotes; HCV- – HCV-negative group; HCV+ – HCV-positive group; HCV CR – group in HCV clinical remission ; M – mutant; wt – wild type




Figure 3 FIB-4 index in all patients with different *ABCB1* and *CYP2B6* variants. H – heterozygotes; M – mutant; wt – wild type

methadone metabolism than those with the GG genotype. In both SNPs of the *CYP3A4* gene the wild genotype had a slower methadone metabolism than the heterozygous genotype.

Although several studies have suggested an association between genetic variability and methadone metabolism, our results showed no significant difference in methadone-to-EDDP ratio between the SNP genotypes. For *ABCB1* rs1045642 it was $p=0.3772$ (ANOVA $F=1.005$), for *CYP2B6* rs3745274 $p=0.6909$ ($F=0.374$), and for *CYP3A4* rs2242480 $p=0.6533$ ($F=0.4313$).

Even within the groups divided by HCV status this difference was not significant ($p>0.05$) (Figure 2). In the HCV+ group, the methadone-to-EDDP ratio was similar for all three *ABCB1* genotypes and slightly higher in patients with the mutated *CYP2B6* genotype.

The liver is the primary target organ of HCV infection and is the main organ responsible for metabolism of drugs. Wu et al. (16) reported that HCV affected methadone metabolism in MMT patients. Our results seem to confirm this finding, as the severity of liver damage (median FIB-4 index) was the highest in HCV patients, who also showed the slowest methadone metabolism (the highest methadone-to-EDDP ratio; Table 1).

Figure 3 shows FIB-4 indices relative to the *ABCB1* and *CYP2B6* gene polymorphisms for all 35 patients. The median FIB-4 index in both examined genes was higher in patients with the mutated genotype. However, we found no statistically significant difference in FIB-4 index between the SNP genotypes. For *ABCB1* rs1045642 it was $p=0.4465$ (ANOVA $F=0.8269$) and for *CYP2B6* rs3745274 $p=0.1551$ ($F=1.977$).

In conclusion, our study found no significant influence of the established genetic polymorphisms in our patients with methadone metabolism. Similar has been reported by Fonseca et al. (17), who found negligible impact of the *CYP3A5*, *CYP2B6*, *CYP2C9*, *CYP2C19*, and *ABCB1* genetic polymorphisms on *S*-methadone metabolite plasma concentrations (16).

The only major influence on the methadone-to-EDDP ratio in HCV+ patients we found was the stage of liver damage. HCV- and HCV+ patients were taking similar methadone doses. The FIB-4 index and the methadone-to-EDDP ratio in HCV- patients were lower, regardless of the genotype.

However, our conclusion should be taken with reserve, as this study had a small sample size. Future research should therefore involve more MMT patients.

Acknowledgements

We would like to thank professor Sonja Koren for proofreading the manuscript.

REFERENCES

- Karch SB, editor. Drug Abuse Handbook. 2nd ed. Boca Raton: CRC Press; 2006.
- Foster DJ, Somogyi AA, Bochner F. Methadone *N*-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. *Br J Clin Pharmacol* 1999;47:403-12. doi: 10.1046/j.1365-2125.1999.00921.x
- Total RA, Allen KE, Sheffels P, Whittington D, Kharasch ED. Enantiomeric metabolic interactions and stereoselective human methadone metabolism. *J Pharmacol Exp Ther* 2007;321:389-99. doi: 10.1124/jpet.106.117580
- Yongfang Li, Kantelip JP, Gerritsen-van Schieveen P, Davani S. Interindividual variability of methadone response: impact of genetic polymorphism. *Mol Diagn Ther* 2008;12:109-24. doi: 10.1007/BF03256276
- Coller JK, Barratt DT, Dahlen K, Loennechen MH, Somogyi AA. *ABCB1* genetic variability and methadone dosage requirements in opioid-dependent individuals. *Clin Pharmacol Ther* 2006;80:682-90. doi: 10.1016/j.clpt.2006.09.011
- Richards-Waugh LL, Primerano DA, Dementieva Y, Kraner JC, Rankin GO. Fatal methadone toxicity: potential role of CYP3A4 genetic polymorphism. *J Anal Toxicol* 2014;38:541-7. doi: 10.1093/jat/bku091
- Sutlović D, Ključević Z, Slisković L, Susnjarić H, Visković I, Definisin-Gojanović M. Methadone maintenance treatment: a 15-year retrospective study in Split-Dalmatia County, Croatia. *Ther Drug Monit* 2018;40:486-94. doi: 10.1097/FTD.0000000000000519
- Ključević Z, Benzon B, Ključević N, Veršić Bratinčević M, Sutlović D. Liver damage indices as a tool for modifying methadone maintenance treatment: a cross-sectional study. *Croat Med J* 2018;59:298-306. doi: 10.3325/cmj.2018.59.298
- Bogdanović Z, Marinović-Terzić I, Kuret S, Jerončić A, Bradarić N, Forempoher G, Polašek O, Andelinović Š, Terzić J. The impact of IL-6 and IL-28B genepolymorphisms on treatment outcome of chronic hepatitis C infection among intravenous drug users in Croatia. *PeerJ* 2016;4:e2576. doi: 10.7717/peerj.2576
- Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, Sulkowski MS, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology* 2006;43:1317-25. doi: 10.1002/hep.21178
- Veršić Bratinčević M, Visković T, Sutlović D. Comparison of the solid phase and liquid-liquid extraction methods for methadone determination in human serum and whole blood samples using gas chromatography/mass spectrometry. *Arh Hig Rada Toksikol* 2017;68:308-14. doi: 10.1515/aiht-2017-68-2953
- Laboratory of Immunogenomics and Immunoproteomics. Files [displayed 26 August 2020]. Available at <http://www.dr-petrek.eu/documents/HWE.xls>
- Total RA, Sheffels P, Roberts T, Whittington D, Thummel K, Kharasch ED. Role of CYP2B6 in stereoselective human methadone metabolism. *Anesthesiology* 2008;108:363-74. doi: 10.1097/ALN.0b013e3181642938
- Ahmad T, Sabet S, Primerano DA, Richards-Waugh LL, Rankin G. Tell-tale SNPs: The role of CYP2B6 in methadone

- fatalities. *J Anal Toxicol* 2017;41:325–33. doi: 10.1093/jat/bkw135
15. Dennis BB, Bawor M, Thabane L, Sohani Z, Samaan Z. Impact of *ABCB1* and *CYP2B6* genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: A systematic review and meta-analysis. *PLoS One* 2014;9(1):e86114. doi: 10.1371/journal.pone.0086114
 16. Wu SL, Wang SC, Tsou HH, Kuo HW, Ho IK, Liu SW, Hsu Y-T, Chang Y-S, Liu Y-L. Hepatitis C virus infection influences the S-methadone metabolite plasma concentration. *PLoS One* 2013;8(7):e69310. doi: 10.1371/journal.pone.0069310
 17. Fonseca F, de la Torre, Diaz L, Pastor A, Cuyàs E, Pizarro N, Khymenets O, Farré M, Torrens M. Contribution of cytochrome P450 and *ABCB1* genetic variability on methadone pharmacokinetics, dose requirements, and response. *PLoS One* 2011;12:e19527. doi: 10.1371/journal.pone.0019527

Polimorfizmi gena *ABCB1*, *CYP2B6* i *CYP3A4* ne utječu na metadonsku terapiju održavanja u bolesnika s HCV-om

Cilj ovoga istraživanja bio je utvrditi utjecaj polimorfizama gena *ABCB1*, *CYP2B6* i *CYP3A4* na metabolizam metadona u bolesnika/ovisnika s pozitivnim nalazom virusa hepatitisa C (HCV) na metadonskoj terapiji održavanja. Istraživanje je provedeno na uzorku od 35 sudionika na metadonskoj terapiji održavanja, podijeljenih u sljedeće skupine: HCV pozitivni (N=12), HCV negativni (N=16) i oni s kliničkom remisijom HCV-a (CR) (N=7). Koncentracije metadona i njegova glavnog metabolita 2-etiliden-1,5-dimetil-3,3-difenilpirolidina (EDDP) utvrđene su plinskom kromatografijom – masenom spektrometrijom. U sudionika su analizirani genski polimorfizmi *ABCB1* rs1045642, *CYP2B6* rs3745274, *CYP3A4* rs2242480 i *CYP3A4* rs2740574. Jednosmjerna analiza varijance (engl. *one-way ANOVA*) nije pokazala statistički značajne razlike između genotipova jednonukleotidnih polimorfizama (engl. *single-nucleotide polymorphism*, krat. SNP) u omjeru koncentracije metadona i EDDP-a ($p=0,3772$ za *ABCB1* rs1045642; $p=0,6909$ za *CYP2B6* rs3745274 $F=0,374$ i $p=0,6533$ za *CYP3A4* rs2242480). Nijedan od četiriju analiziranih SNP genotipova nije korelirao s omjerom koncentracije metadona i EDDP-a. U bolesnika/ovisnika koji su bili pozitivni na HCV na taj je omjer ponajviše utjecao stupanj oštećenja jetre.

KLJUČNE RIJEČI: EDDP; genotipiziranje; hepatitis C; jednonukleotidni polimorfizmi; oštećenje jetre; SNP